H ypertrophic cardiomyopathy is a major cause of morbidity and mortality in industrialized countries.
affects cardiac function as suggested by the attenuation of cytokine-induced cardiomyopathy, 7 exacerbation of adverse remodeling in experimental myocardial infarction, 8 and exacerbation of pressure overload by transverse aortic constriction. 9 However, the molecular mechanism(s) of MMP-2 in these models is lacking. Moreover, the purported role of decreased extracellular remodeling because of lack of MMP-2 is both unlikely and unproven to account for the observed phenotypes in these models of disease. The potential contribution of inflammatory pathways regulated by MMP-2 is unclear.
A mechanism of hypertrophic cardiac disease relevant to this study depends on the activity of a ubiquitous enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). 10 HMGCR catalyzes the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, 11 which is the rate-limiting step in a series of enzymatic conversions that transform 3-hydroxy-3-methylglutaryl-coenzyme A to 5-carbon, 15-carbon, and eventually 20-carbon activated isoprenoids, such as isopentenyl pyrophosphate, farnesyl pyrophosphate and geranylgeranyl pyrophosphate. Notably, isoprenylation of small GTPases of the Ras superfamily switch on or off intracellular signaling of hypertrophy, fibrosis, and oxidative stress in response to G protein-coupled receptor agonists. 12 HMGCR is strongly regulated at the transcriptional level by sterol regulatory element-binding protein (SREBP)-2. 11 Here, we show that MMP-2 deficiency predisposes to cardiac dysfunction as well as metabolic and inflammatory gene expression dysregulation. This complex phenotype is, at least in part, a consequence of the cardiac SREBP-2/HMGCR pathway being upregulated in the absence of MMP-2.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Animal Models
Animal protocols were conducted in accordance with institutional guidelines issued by the Canadian Council on Animal Care and US National Institutes of Health. All animals were fed regular chow and housed at the University of Alberta. Male C57BL/6 mice were purchased from Charles River (Wilmington, MA). Male Mmp2 −/− mice were bred and housed at the University of Alberta. The mice used in the studies were 11 to 14 weeks old. ALZET osmotic minipumps (DURECT Corporation, Cupertino, CA) delivering either PBS or Ang II (1.4 or 2.0 mg/kg/day; EMD Millipore, Billerica, MA) were implanted subcutaneously on the posterior midsection of mice anaesthetized by isofluorane.
Statistical Analysis
Results were analyzed using 1-way ANOVA (between multiple groups) or t test (between 2 groups; Systat SigmaPlot 11 software). All data are reported as means±SEM.
Results

MMP-2 Deficiency Predisposes to Ang II-Induced Cardiac Hypertrophy
Ang II infusion induced systemic hypertension in wildtype (WT), as expected ( Figure S1 in the online-only Data Supplement). We observed no significant differences in either time course (data not shown) or magnitude of maximal systolic blood pressure in Mmp2 −/− mice versus WT mice ( Figure S1 ). Within 2 weeks of Ang II infusion, mice of either genotype developed maximal cardiac hypertrophy, as indicated by the relative increase in the heart weight to either body weight or tibia length ( Figure 1A ; Figure S2 ).
Interestingly, in Mmp2 −/− mice, hypertrophy developed earlier and to a greater extent than WT mice ( Figure 1A) . Fibrosis in the Ang II model was both interstitial and perivascular ( Figure 1B) , with a significant overexpression of marker genes of cardiac fibrosis and hypertrophy as assessed by quantitative reverse transcription polymerase chain reaction ( Figure 1C-1F) . No spontaneous cardiac hypertrophy was observed. These data suggested that in agonist-induced hypertrophic heart disease, MMP-2 may be cardioprotective.
Deficiency of MMP-2 Affects Cardiac Expression of Metabolic and Inflammatory Genes
We next explored whether the MMP-2 deficiency predisposed to hypertensive cardiac disease by way of altering the cardiac gene expression. Based on our hypothesis 13 that alterations in inflammatory or lipid metabolic genes may underlie the development of heart disease, which was being pursued by independent lines of research in our laboratory, we examined the cardiac expression of 56 genes comprising inflammatory and lipid metabolic transcription factors, enzymes, and mediators. The analysis revealed a large elevation of Srebf2 and Hmgcr (genes encoding SREBP-2 and HMGCR, respectively), as well as a decreased expression of Nr1h3 (which encodes a liver X receptor-α, a major lipid metabolic transcription factor) in Mmp2 −/− relative to WT mice ( Figure 2A ). Markers of inflammation, including chemokines of the C-C motif ligand family: Ccl5, Ccl2, and Ccl6, were among the most upregulated of the genes measured. Similar to whole hearts, isolated cardiomyocytes demonstrated an upregulation of Srebf2, Hmgcr, and Ldlr ( Figure S3 ). These data show the role of MMP-2 in modulating cardiac inflammation and lipid metabolic gene expression.
Cardiac SREBP-2 Transcriptional Pathway Is a Target of Ang II in Cardiac Hypertrophy
We next examined the transcriptional regulation of cardiac HMGCR in Ang II-induced hypertensive cardiac disease. In WT mice, reverse transcription polymerase chain reaction analysis indicated an increase in HMGCR mRNA within the first week of Ang II infusion, followed by an eventual normalization ( Figure 3A) . In contrast to WT mice, the baseline expression of HMGCR in the Mmp2 −/− mice was upregulated. This upregulation persisted for the first week of Ang II infusion, but by week 2 decreased to WT levels. In both WT and Mmp2 −/− mice, SREBP-2 (transcriptional regulator of HMGCR and low-density lipoprotein receptor) and lowdensity lipoprotein receptor transcription followed a similar pattern of expression as HMGCR over the course of Ang II infusion ( Figure 3B and 3C).
Interestingly, HMGCR protein immunoreactivity in Mmp2 −/− hearts was elevated at both baseline and after 2 weeks of Ang II ( Figure 3D ). Because HMGCR mediates pathways of cardiac hypertrophy, 10, 14 we hypothesized that the baseline elevation of HMGCR in Mmp2 −/− mice could contribute to cardiac hypertrophy.
MMP-2-Dependent Negative Regulation of HMGCR Protects Against Pathological Cardiac Hypertrophy and Fibrosis
To examine the role of HMGCR in the pathology of hypertrophic heart disease, we administered lovastatin to mice infused with Ang II. Treatment with lovastatin dose dependently prevented Ang II-induced cardiac hypertrophy in Mmp2 −/− mice, as well as in WT mice, confirming the key contribution of HMGCR to Ang II-induced cardiac disease in both genotypes ( Figure 4A ). When lovastatin was given at a dose of 54 mg/kg/day, hypertrophy and fibrosis marker gene expression were significantly reduced in the hearts of both WT and
Mmp2
−/− infused with Ang II ( Figure 4B ). However, Mmp2
−/− mice required a 2-fold higher dose of lovastatin to prevent the development of cardiac hypertrophy, which was consistent with their higher HMGCR levels. The elevated expression of inflammatory markers in Mmp2 −/− mice was, in part, reduced by administration of lovastatin ( Figure 4B ).
Discussion
We have found that lack of MMP-2 results in significant alteration of cardiac gene expression. Among the most upregulated genes in the left ventricle of mice are SREBP-2 and targets thereof, such as HMGCR (rate-limiting enzyme in the mevalonate pathway). In addition, we found that MMP-2 deficiency upregulates proinflammatory genes, as well as predisposes to cardiac hypertrophy. Indeed, a major finding of this study is that, during the development of hypertensive cardiac disease, MMP-2 is cardioprotective through a novel mechanism involving negative regulation of the SREBP-2/HMGCR axis of cardiac hypertrophy ( Figure 4C ). As a consequence of their upregulated cardiac SREBP-2/HMGCR pathway, Mmp2 −/− mice were less susceptible to cardioprotection by lovastatin.
MMPs have long been implicated in the modulation of cardiac remodeling, with most studies centered on the proteolytic cleavage of substrates, such as extracellular matrix proteins, growth factors, and receptors. 15, 16 Here, we show that MMP-2 negatively regulates a fundamental metabolic mechanism 
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and may thus affect the development and severity of cardiac disease. Indeed, Mmp2 −/− mice had surprisingly high baseline mRNA levels of cardiac SREBP-2, a major transcription factor for HMGCR and low-density lipoprotein receptor genes. We have previously observed that MMP-2 is elevated in the heart during the early stages of Ang II-induced hypertensive heart disease, but the function of this augmentation has been unclear. 17 Elevated MMP-2 activity has been proposed to be detrimental after myocardial infarction. 8, 9 Here, we observed that MMP-2 deficiency predisposes to cardiac hypertrophy, suggesting that cardiac MMP-2 overexpression in the hypertensive heart may be cardioprotetective, at least in part, by preventing excessive expression of cardiac HMGCR. However, cardioprotection by MMP-2 is eventually overcome by Ang II because the characteristically high baseline mRNA levels of SREBP-2 and HMGCR in Mmp2 −/− mice declined to WT levels once cardiac hypertrophy was established (around week 2 on Ang II). Therefore, MMP-2 cardioprotection has a limited time window.
Further evidence implicating the MMP-2/HMGCR axis in the cardiac disease development came from pharmacological studies where we used lovastatin to inhibit HMGCR. Lovastatin attenuated the induction of hypertrophy and fibrosis marker genes in both Mmp2 −/− and WT mice. However, compared with WT mice, Mmp2 −/− mice had reduced responsiveness to lovastatin. These results indicate that higher baseline levels of HMGCR predispose to cardiac disease in Mmp2 −/− mice, and further implicate HMGCR in pathological cardiac remodeling. 10, 14 Although this study advances our understanding of the significance of MMP-2 for the development of cardiac disease, the question as to how MMP-2 negatively regulates SREBP-2 transcription remains and is being actively investigated by our laboratory.
Previous studies have established that one of the mechanisms whereby HMGCR, activity contributes to cardiac hypertrophy is through the synthesis of mevalonatea common precursor of cholesterol and isoprenoids. Synthesis of isoprenoids is necessary for the signaling activity of small GTPases, such as Rac1 and Rho, and previous studies have demonstrated that Ang II induces the development of cardiac hypertrophy through isoprenylation of these GTPases, indicating the prohypertrophic potential of isoprenoids synthesized downstream of HMGCR. 10, 14 Isoprenylation of Rho is required for cardiac hypertrophy signaling through mitogen-activated protein kinases, whereas isoprenylation of Rac1 contributes through activation of nicotinamide adenine dinucleotide phosphate oxidase and superoxide production. Synthesis of cholesterol does not seem to be a major contributor to cardiac hypertrophy signaling at least in normocholesterolemic mice. In line with this notion, statins have been shown to protect from cardiac hypertrophy without causing any detectable alteration in low-density lipoprotein-cholesterol levels. 10, 14 In rat cardiomyocytes, HMGCR activity has been suggested to account for the intracellular cholesterol levels, 18, 19 although cardiomyocytes may acquire cholesterol from the circulation. 20 Recent metabolites profile studies using mass spectrometry-based analysis combined with high-temperature gas chromatography show an 7-fold increase in cholesterol levels in hypertrophic cardiac tissues. 21 However, in our studies, mice fed chow supplemented with ≤1.5% cholesterol for 15 days did not exhibit significant differences in the magnitude of cardiac hypertrophy induced by Ang II (unpublished observations). Although the role of cardiac cholesterol in the pathogenesis of hypertensive heart disease remains unclear, high levels of cholesterol in the circulation do correlate with increased risk of atherosclerosis and coronary artery disease.
Clinical Significances
Our findings suggest that therapeutic agents targeting MMPs in the context of cardiovascular and noncardiovascular conditions could be detrimental for heart function by decreasing cardiac MMP-2 levels. This is important because MMPs remain attractive therapeutic targets in the context of cardiovascular conditions (eg, atherosclerosis, ischemia reperfusion, hypertrophic heart disease, and postmyocardial infarction), as well as in noncardiovascular disorders (cancer, rheumatoid arthritis, and inflammation).
Our findings can also help explain the results of human studies showing that MMP-2 expression is negatively correlated with the susceptibility to hypertensive heart disease. Two striking examples are (1) functional genetic polymorphisms, which increase MMP-2 gene expression, reportedly protects against cardiac remodeling including increases in end-diastolic diameter and left ventricular mass index in hypertensive subjects and 22 (2) a rare panethnic genetic disease of deficiency in human MMP-2 enzyme activity affects some Saudi Arabian, Indian, and Turkish family with congenital heart disease, including atrial and ventricular septal defects. 23 Our findings suggest a metabolic basis for the presentation of deleterious proinflammatory cardiac phenotypes in MMP-2-deficient humans. Future research may reveal to what extent MMP-2 upregulation by genetic or pharmacological means can be exploited to either prevent or ameliorate hypertensive heart disease.
Perspectives
MMP-2 mediates a novel metabolic mechanism of cardioprotection involving negative regulation of the SREBP-2/ HMGCR pathway in the heart and, thereby, inhibition of pathological cardiac remodeling. Importantly, our data suggest that caution should be exercised before implementing therapeutic strategies targeting MMP-2 because MMP-2 deficiency could predispose to cardiac dysfunction. 
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